Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Bladder Transitional Cell Carcinoma
Fred Hutchinson Cancer Centerantibody_drug_conjugatePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 89/ 100
Competitive context
36 Active assets in the Bladder Transitional Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cis-Diamminedichloroplatinum Ii Nagoya University | Phase 3 | BB |
Atezolizumab KaliVir Immunotherapeutics | Phase 3 | BB |
Carboplatin Jonsson Comprehensive Cancer Center | Phase 2 | BB |
Pembrolizumab Fred Hutchinson Cancer Center | Phase 3 | BB |
Nivolumab Nagoya University | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →